MedTrace Logo

Everolimus and Letrozole or Hormonal Therapy to Treat Endometrial Cancer

NCT02228681 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 74

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

The main purpose of this study is to evaluate the effectiveness of the combination of the drugs Everolimus and Letrozole compared to Tamoxifen and Medroxyprogesterone acetate in treating endometrial cancer and to determine the types and severity of side effects caused by treatment with these drug combinations.

Conditions

  • Advanced, Persistent, or Recurrent Endometrial Cancer

Interventions

DRUG

Everolimus

10mg daily by mouth

DRUG

Tamoxifen

20 mg daily by mouth on alternating weeks (even numbered) weeks

DRUG

Letrozole

2.5mg once a day by mouth

DRUG

Medroxyprogesterone Acetate

200 mg daily by mouth

Sponsors & Collaborators

Principal Investigators

  • Brian Slomovitz, MD · Gynecologic Oncology Group

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-21
Primary Completion
2018-01-31
Completion
2024-08-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02228681 on ClinicalTrials.gov